ReviewCurrent pharmaceutical design2025
Advances in Parenteral Nanocarriers and Delivery Devices: A Comprehensive Review.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The field of drug delivery has witnessed significant advancements with the emergence of nanocarriers and advanced delivery devices for parenteral administration. Nanocarriers, a prominent topic in drug delivery, are introduced with an emphasis on their significance and diverse applications A critical analysis compares conventional injectables with parenteral nanocarriers, focusing on identifying limitations and proposing innovative solutions to enhance their efficacy and stability. The subsequent discussion delves into advanced parenteral nanocarriers, including solid lipid nanoparticles, liposomes, polymeric nanoparticles, metallic nanoparticles, dendrimers, carbon nanotubes, and graphene. Each nanoparticle type is assessed based on its unique properties, advancements in research, and potential applications in parenteral drug delivery. Furthermore, advanced sterile drug delivery devices are explored, highlighting their role in enhancing precision and efficacy in parenteral administration. A comprehensive market analysis provides insights into current trends, key players, and future prospects in parenteral nanocarriers. Lastly, regulatory perspectives are discussed, focusing on the challenges and considerations in approving and regulating parenteral nanocarriers. The paper concludes with a summary of key findings and implications for future research and development in this rapidly evolving field of parenteral nanocarriers.
Indexed as
Identifiers
40143399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.